Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Pilot study assesses veliparib/temozolomide combination in metastatic CRPC

Feb. 7, 2012

Phase II trial assesses RO-4929097 in prostate cancer

Feb. 6, 2012

OGX-427 shows signs of efficacy in phase II trial

Feb. 6, 2012

Cixutumumab and ramucirumab studied in metastatic castration-resistant prostate cancer

Feb. 6, 2012

Rilotumumab does not improve efficacy of combination therapy in prostate cancer trial

Feb. 6, 2012

VT-464 reduces tumor growth in prostate cancer model

Feb. 3, 2012

ARN-509 is well tolerated in phase I/II study

Feb. 3, 2012

Studies detail beta-amyloid detection with florbetapir F 18 PET

Jan. 27, 2012

Liposomal irinotecan shows benefit in metastatic colorectal cancer

Jan. 27, 2012

Panobinostat trial in colorectal cancer yields mixed results

Jan. 26, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...